253 related articles for article (PubMed ID: 36274133)
1. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U
BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133
[TBL] [Abstract][Full Text] [Related]
2. Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel.
Dufresne A; Attignon V; Ferrari A; Tonon L; Boyault S; Tabone-Eglinger S; Cassier P; Trédan O; Corradini N; Vinceneux A; Swalduz A; Viari A; Chabaud S; Pérol D; Blay JY; Saintigny P
Cancer Med; 2024 Apr; 13(7):e7115. PubMed ID: 38553950
[TBL] [Abstract][Full Text] [Related]
3. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
Oberg JA; Glade Bender JL; Sulis ML; Pendrick D; Sireci AN; Hsiao SJ; Turk AT; Dela Cruz FS; Hibshoosh H; Remotti H; Zylber RJ; Pang J; Diolaiti D; Koval C; Andrews SJ; Garvin JH; Yamashiro DJ; Chung WK; Emerson SG; Nagy PL; Mansukhani MM; Kung AL
Genome Med; 2016 Dec; 8(1):133. PubMed ID: 28007021
[TBL] [Abstract][Full Text] [Related]
4. Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance.
Walters MK; Ackerman AT; Weese JL; Ruggeri A; Mullane MP; Hunt A; Wilson A; Ramczyk BL; Thompson MA
JCO Precis Oncol; 2022 Oct; 6():e2200132. PubMed ID: 36265115
[TBL] [Abstract][Full Text] [Related]
5. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
[TBL] [Abstract][Full Text] [Related]
6. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
[TBL] [Abstract][Full Text] [Related]
7. Support of a molecular tumour board by an evidence-based decision management system for precision oncology.
Lamping M; Benary M; Leyvraz S; Messerschmidt C; Blanc E; Kessler T; Schütte M; Lenze D; Jöhrens K; Burock S; Klinghammer K; Ochsenreither S; Sers C; Schäfer R; Tinhofer I; Beule D; Klauschen F; Yaspo ML; Keilholz U; Rieke DT
Eur J Cancer; 2020 Mar; 127():41-51. PubMed ID: 31982633
[TBL] [Abstract][Full Text] [Related]
8. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
[TBL] [Abstract][Full Text] [Related]
9. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
10. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
[TBL] [Abstract][Full Text] [Related]
12. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
13. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.
Van Allen EM; Robinson D; Morrissey C; Pritchard C; Imamovic A; Carter S; Rosenberg M; McKenna A; Wu YM; Cao X; Chinnaiyan A; Garraway L; Nelson PS
Oncotarget; 2016 Aug; 7(33):52888-52899. PubMed ID: 27167109
[TBL] [Abstract][Full Text] [Related]
14. Implementation of a molecular tumor board at a regional level to improve access to targeted therapy.
Bourien H; Lespagnol A; Campillo-Gimenez B; Felten-Vinot I; Metges JP; Corre R; Lesimple T; le Marechal C; Boussemart L; Kammerer-Jacquet SF; le Gall E; Denoual F; de Tayrac M; Galibert MD; Mosser J; Edeline J
Int J Clin Oncol; 2020 Jul; 25(7):1234-1241. PubMed ID: 32215806
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.
Yoon S; Kim M; Hong YS; Kim HS; Kim ST; Kim J; Yun H; Yoo C; Ahn HK; Kim HS; Lee IH; Kim IH; Park I; Jeong JH; Cheon J; Kim JW; Yun J; Lim SM; Cha Y; Jang SJ; Zang DY; Kim TW; Kang JH; Kim JH
Cancer Res Treat; 2022 Jan; 54(1):1-9. PubMed ID: 34902959
[TBL] [Abstract][Full Text] [Related]
16. Personalized oncology through integrative high-throughput sequencing: a pilot study.
Roychowdhury S; Iyer MK; Robinson DR; Lonigro RJ; Wu YM; Cao X; Kalyana-Sundaram S; Sam L; Balbin OA; Quist MJ; Barrette T; Everett J; Siddiqui J; Kunju LP; Navone N; Araujo JC; Troncoso P; Logothetis CJ; Innis JW; Smith DC; Lao CD; Kim SY; Roberts JS; Gruber SB; Pienta KJ; Talpaz M; Chinnaiyan AM
Sci Transl Med; 2011 Nov; 3(111):111ra121. PubMed ID: 22133722
[TBL] [Abstract][Full Text] [Related]
17. Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.
Jobanputra V; Wrzeszczynski KO; Buttner R; Caldas C; Cuppen E; Grimmond S; Haferlach T; Mullighan C; Schuh A; Elemento O
Semin Cancer Biol; 2022 Sep; 84():23-31. PubMed ID: 34256129
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
Larson KL; Huang B; Weiss HL; Hull P; Westgate PM; Miller RW; Arnold SM; Kolesar JM
JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34632252
[TBL] [Abstract][Full Text] [Related]
19. Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
Mathew A; Davis S; Boby JM; R I A; Suryavanshi M; Dawood SS; Panda PK; Nag SM; Das A; Rohatgi N; Popat S; Shah RNH; Thampy C; Parikh AR; Yadav S; Mehta P; Singh R; Mukherji D; Shilpakar R; Mullapally SK; Sirohi B
JCO Glob Oncol; 2024 Mar; 10():e2300330. PubMed ID: 38484196
[TBL] [Abstract][Full Text] [Related]
20. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
Langenberg KPS; Meister MT; Bakhuizen JJ; Boer JM; van Eijkelenburg NKA; Hulleman E; Ilan U; Looze EJ; Dierselhuis MP; van der Lugt J; Breunis W; Schild LG; Ober K; van Hooff SR; Scheijde-Vermeulen MA; Hiemcke-Jiwa LS; Flucke UE; Kranendonk MEG; Wesseling P; Sonneveld E; Punt S; Boltjes A; van Dijk F; Verwiel ETP; Volckmann R; Hehir-Kwa JY; Kester LA; Koudijs MMJ; Waanders E; Holstege FCP; Vormoor HJ; Hoving EW; van Noesel MM; Pieters R; Kool M; Stumpf M; Blattner-Johnson M; Balasubramanian GP; Van Tilburg CM; Jones BC; Jones DTW; Witt O; Pfister SM; Jongmans MCJ; Kuiper RP; de Krijger RR; Wijnen MHW; den Boer ML; Zwaan CM; Kemmeren P; Koster J; Tops BBJ; Goemans BF; Molenaar JJ
Eur J Cancer; 2022 Nov; 175():311-325. PubMed ID: 36182817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
